2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002

Vasogen to Conduct Video Webcast and Conference Call of Annual and Special Meeting

Toronto, Ontario - March 14, 2005

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease, will conduct a video webcast and conference call of its Annual and Special Meeting being held at the TSX Conference Centre Wednesday, March 16, 2005, at 4:30 p.m. EST (Toronto time).

To participate in the video webcast:

Please log onto Vasogen’s website at: www.vasogen.com. An archived replay will be available following the presentation.

To participate via telephone conference call:

Participants are invited to attend by connecting 10 minutes prior to one of the following:

Direct Dial	416-640-1907
Toll-free	1-800-796-7558

Those participating via conference call can also log onto www.vasogen.com and follow the Powerpoint presentation.

A Question and Answer session will be held after the presentation and those participating by phone will be directed to get in queue.

A re-broadcast of the audio presentation may be accessed by:

Direct Dial	416-640-1917
Toll-free	1-877-289-8525 Pin code: 21117432#

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company’s lead product, the CelacadeÔ technology, is currently in two pivotal phase III clinical trials in life-threatening cardiovascular conditions with significant unmet needs. The 500-patient pivotal phase III SIMPADICO trial, which has completed patient enrolment, is designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. The 2,000-patient pivotal phase III ACCLAIM trial, ongoing at more than 150 clinical centers in North America, Europe, and Israel, is designed to further investigate the use of Celacade technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders, which include such devastating disorders as Parkinson’s disease and Alzheimer’s disease. VP025, the lead product candidate from this new class of drugs, is now in phase I clinical development.